The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.
Open accessAbstract
Activated components of the complement system are potent mediators of inflammation that may play an important role in numerous disease states. For example, they have been implicated in the pathogenesis of inflammatory joint diseases including rheumatoid arthritis (RA). To target complement activation in immune-mediated joint inflammation, we have utilized monoclonal antibodies (mAbs) that inhibit the complement cascade at C5, blocking the generation of the major chemotactic and proinflammatory factors C5a and C5b-9. In this study, we demonstrate the efficacy of a mAb specific for murine C5 in the treatment of collagen-induced arthritis, an animal model for RA. We show that systemic administration of the anti-C5 mAb effectively inhibits terminal complement activation in vivo and prevents the onset of arthritis in immunized animals. Most important, anti-C5 mAb treatment is also highly effective in ameliorating established disease. These results demonstrate a critical role for activated terminal complement components not only in the induction but also in the progression of collagen-induced arthritis and suggest that C5 may be an attractive therapeutic target in RA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wooley, P. H., Luthra, H. S., Stuart, J. M., & David, C. S. (1981) · The Journal of experimental medicine · doi:10.1084/jem.154.3.688 · Cited by 687
C5A Anaphylatoxin and Its Seven Transmembrane-Segment Receptor
Gerard, C., & Gerard, N. P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.004015 · Cited by 416
Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4.
Ranges, G. E., Sriram, S., & Cooper, S. M. (1985) · The Journal of experimental medicine · doi:10.1084/jem.162.3.1105 · Cited by 365
Stuart, J. (1984) · Annual Review of Immunology · doi:10.1146/annurev.immunol.2.1.199 · Cited by 186
Development of C5a receptor antagonists. Differential loss of functional responses.
Konteatis, Z. D., Siciliano, S. J., Riper, G. V., Molineaux, C. J., Pandya, S., Fischer, P. A., Rosen, H., Mumford, R. A., & Springer, M. S. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.9.4200 · Cited by 151
Membrane signaling by complement C5b-9, the membrane attack complex
Nicholson-Weller, A., & Halperin, J. A. (1993) · Immunologic Research · doi:10.1007/bf02918256 · Cited by 149
Brodeur, J. P., Ruddy, S., Schwartz, L. B., & Moxley, G. F. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780341209 · Cited by 133
Frei, Y., Lambris, J. D., & Stockinger, B. (1987) · Molecular and Cellular Probes · doi:10.1016/0890-8508(87)90022-3 · Cited by 90
Inhibition of Terminal Complement Complex Formation and Cell Lysis by Monoclonal Antibodies
Würzner, R., Schulze, M., Happe, L., Franzke, A., BIEBER, F. A., Oppermann, M., & Götze, O. (2017) · Complement and Inflammation · doi:10.1159/000463204 · Cited by 90
Högåsen, K., Mollnes, T. E., Harboe, M., Götze, O., Hammer, H. B., & Oppermann, M. (1995) · PubMed · Cited by 82
Cited by
TRAF1–C5 as a Risk Locus for Rheumatoid Arthritis — A Genomewide Study
Plenge, R. M., Seielstad, M., Padyukov, L., Lee, A. T., Remmers, E. F., Ding, B., Liew, A., Khalili, H., Chandrasekaran, A., Davies, L. R. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073491 · Cited by 823
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Arthritis Critically Dependent on Innate Immune System Players
Ji, H., Ohmura, K., Mahmood, U., Lee, D. M., Hofhuis, F. M. A., Boackle, S. A., Takahashi, K., Holers, V. M., Walport, M., Gerard, C., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00275-3 · Cited by 693
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318817 · Cited by 594
Wipke, B. T., & Allen, P. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.3.1601 · Cited by 585
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome
Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J. M., Kraus, D., Hollmann, T. J., Casali, P., Caroll, M. C., Wetsel, R. A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18817 · Cited by 575
Leffler, J., Martin, M., Gullstrand, B., Tydén, H., Lood, C., Truedsson, L., Bengtsson, A. A., & Blom, A. M. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102404 · Cited by 516
Girardi, G., Yarilin, D., Thurman, J. M., Holers, V. M., & Salmon, J. E. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061022 · Cited by 508
Complement-targeted therapeutics
Ricklin, D., & Lambris, J. D. (2007) · Nature Biotechnology · doi:10.1038/nbt1342 · Cited by 481
Predominant role for C5b-9 in renal ischemia/reperfusion injury
Zhou, W., Farrar, C. A., Abe, K., Pratt, J. R., Marsh, J. E., Wang, Y., Stahl, G. L., & Sacks, S. H. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8621 · Cited by 465
Self-citationMollnes, T. E., Brekke, O., Fung, M. S. C., Fure, H., Christiansen, D., Bergseth, G., Videm, V., Lappegård, K. T., Köhl, J., & Lambris, J. D. (2002) · PubMed · doi:10.1182/blood.v100.5.1869.h81702001869_1869_1877 · Cited by 455
Complement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma
Karp, C. L., Grupe, A., Schadt, E., Ewart, S. L., Keane-Moore, M., Cuomo, P. J., Köhl, J., Wahl, L., Kuperman, D., Germer, S., et al. (2000) · Nature Immunology · doi:10.1038/79759 · Cited by 378
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
Self-citationPierangeli, S. S., Girardi, G., Vega‐Ostertag, M., Liu, X., Espinola, R. G., & Salmon, J. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21157 · Cited by 362
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Wang, Y., Hu, Q., Madri, J. A., Rollins, S. A., Chodera, A., & Matis, L. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8563 · Cited by 336
Self-citationB cell-deficient mice do not develop type II collagen-induced arthritis (CIA)
Svensson, L., Jirholt, J., Holmdahl, R., & Jansson, L. (2001) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.1998.00529.x · Cited by 314
Kopf, M., Abel, B., Gallimore, A., Carroll, M., & Bachmann, M. F. (2002) · Nature Medicine · doi:10.1038/nm0402-373 · Cited by 311
Utility of animal models for identification of potential therapeutics for rheumatoid arthritis
Hegen, M., Keith, J. C., Collins, M., & Nickerson-Nutter, C. L. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076430 · Cited by 305
Collagen Type II-Specific Monoclonal Antibody-Induced Arthritis in Mice
Nandakumar, K. S., Svensson, L., & Holmdahl, R. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63542-0 · Cited by 294
A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis
Kurreeman, F. A. S., Padyukov, L., Marques, R. B., Schrodi, S. J., Seddighzadeh, M., Stoeken-Rijsbergen, G., van der Helm-van Mil, A. H. M., Allaart, C. F., Verduyn, W., Houwing-Duistermaat, J., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040278 · Cited by 280
Bora, P. S., Sohn, J.-H., Cruz, J. M. C., Jha, P., Nishihori, H., Wang, Y., Kaliappan, S., Kaplan, H. J., & Bora, N. S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.1.491 · Cited by 249
Self-citationThe complement cascade: Yin-Yang in neuroinflammation—neuro-protection and -degeneration
Alexander, J. J., Anderson, A. J., Barnum, S. R., Stevens, B., & Tenner, A. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05668.x · Cited by 177
Contribution of the innate immune system to autoimmune myocarditis: a role for complement
Kaya, Z., Afanasyeva, M., Wang, Y., Dohmen, K. M., Schlichting, J., Tretter, T., Fairweather, D., Holers, V. M., & Rose, N. R. (2001) · Nature Immunology · doi:10.1038/90686 · Cited by 175
Self-citationDistinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis
Campbell, I. K., Gerondakis, S., O’Donnell, K., & Wicks, I. P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8298 · Cited by 168
Kusakabe, J., Hata, K., Miyauchi, H., Tajima, T., Wang, Y., Tamaki, I., Kawasoe, J., Okamura, Y., Zhao, X., Okamoto, T., et al. (2021) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2021.01.001 · Cited by 18
Self-citation
Metadata
- Authors
- Wang, Y., Rollins, S. A., Madri, J. A., & Matis, L. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-09-12
- Volume
- 92
- Issue
- 19
- Pages
- 8955-8959
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2056824071
- Cited by
- 360
- References
- 14
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.